Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906249 | 0.92 | PDGFRB (0.96) | PDGFRB | |
| SCHEMBL3902359 | 0.90 | PDGFRB (0.72) | PDGFRB | |
| SCHEMBL3365435 | 0.90 | PDGFRB (0.73) | PDGFRB | |
| SCHEMBL13114427 | 0.85 | PDGFRB (0.65) | PDGFRB | |
| SCHEMBL3398676 | 0.84 | PDGFRB (0.88) | PDGFRB | |
| SCHEMBL13330468 | 0.83 | PDGFRB (0.88) | PDGFRB | |
| SCHEMBL3364542 | 0.80 | PDGFRB (0.84) | PDGFRB | |
| SCHEMBL3400547 | 0.79 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL3366839 | 0.79 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL6334841 | 0.79 | PDGFRB (0.73) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | claimed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | claimed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, WNK1 | PDGFRB 6/4885 |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | WNK2, CDK5, WNK1 | PDGFRB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.